MA40770B1 - Dérivés d'imidazoles pentacyclic fusionnés - Google Patents

Dérivés d'imidazoles pentacyclic fusionnés

Info

Publication number
MA40770B1
MA40770B1 MA40770A MA40770A MA40770B1 MA 40770 B1 MA40770 B1 MA 40770B1 MA 40770 A MA40770 A MA 40770A MA 40770 A MA40770 A MA 40770A MA 40770 B1 MA40770 B1 MA 40770B1
Authority
MA
Morocco
Prior art keywords
disorders
imidazole derivatives
fused pentacyclic
pentacyclic imidazole
relates
Prior art date
Application number
MA40770A
Other languages
English (en)
Other versions
MA40770A (fr
Inventor
Bruno Filoche-Romme
Haro Garcia Teresa De
Michael Deligny
Jag Paul Heer
Joanna Rachel Quincey
Mengyang Xuan
Zhaoning Zhu
Daniel Christopher Brookings
Mark Daniel Calmiano
Yves Evrard
Martin Clive Hutchings
James Andrew Johnson
Sophie Jadot
Jean Keyaerts
Coss Malcolm Mac
Matthew Duncan Selby
Michael Alan Shaw
Dominique Louis Léon Swinnen
Laurent Schio
Yann Foricher
Original Assignee
Sanofi Sa
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, UCB Biopharma SRL filed Critical Sanofi Sa
Publication of MA40770A publication Critical patent/MA40770A/fr
Publication of MA40770B1 publication Critical patent/MA40770B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne une série de dérivés d'imidazole pentacycliques fusionnés, qui sont de puissants modulateurs de l'activité du tnfa humain, efficaces dans le traitement et/ou la prévention de diverses affections humaines, dont les troubles auto-immuns et inflammatoires; les troubles neurologiques et neurodégénératifs; la douleur et les troubles nociceptifs; les troubles cardiovasculaires; les troubles métaboliques; les troubles oculaires; et les troubles oncologiques. En particulier, la présente invention concerne des dérivés 6,7-dihydro -7,14-méthanobenzimidazo[l, 2-b] [2,5] benzodiazocin-5 (14h)-ones et des analogues de ceux-ci.
MA40770A 2014-10-03 2015-10-02 Dérivés d'imidazoles pentacyclic fusionnés MA40770B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14290299 2014-10-03
EP15162641 2015-04-07
EP15171036 2015-06-08
PCT/EP2015/072868 WO2016050975A1 (fr) 2014-10-03 2015-10-02 Dérivés d'imidazole pentacycliques fusionnés

Publications (2)

Publication Number Publication Date
MA40770A MA40770A (fr) 2021-03-24
MA40770B1 true MA40770B1 (fr) 2021-11-30

Family

ID=54238452

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40770A MA40770B1 (fr) 2014-10-03 2015-10-02 Dérivés d'imidazoles pentacyclic fusionnés

Country Status (36)

Country Link
US (3) US10202405B2 (fr)
EP (1) EP3201196B1 (fr)
JP (1) JP6629847B2 (fr)
KR (1) KR102442235B1 (fr)
CN (1) CN107108672B (fr)
AP (1) AP2017009809A0 (fr)
AU (1) AU2015326798B2 (fr)
BR (1) BR112017006669B1 (fr)
CA (1) CA2962826C (fr)
CL (1) CL2017000787A1 (fr)
CO (1) CO2017003331A2 (fr)
CR (1) CR20170167A (fr)
DK (1) DK3201196T3 (fr)
EA (1) EA032839B1 (fr)
EC (1) ECSP17027306A (fr)
ES (1) ES2885432T3 (fr)
GT (1) GT201700044A (fr)
HR (1) HRP20211605T1 (fr)
HU (1) HUE056133T2 (fr)
IL (1) IL251147B (fr)
LT (1) LT3201196T (fr)
MA (1) MA40770B1 (fr)
MX (1) MX2017004201A (fr)
MY (1) MY181019A (fr)
PE (1) PE20170693A1 (fr)
PH (1) PH12017500414B1 (fr)
PL (1) PL3201196T3 (fr)
RS (1) RS62423B1 (fr)
SG (1) SG11201701796XA (fr)
SI (1) SI3201196T1 (fr)
TN (1) TN2017000083A1 (fr)
TW (1) TWI719949B (fr)
UA (1) UA120764C2 (fr)
UY (1) UY36341A (fr)
WO (1) WO2016050975A1 (fr)
ZA (1) ZA201701946B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108672B (zh) * 2014-10-03 2019-11-08 Ucb生物制药私人有限公司 稠合的五环咪唑衍生物
WO2016168633A1 (fr) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones utilisées en tant que modulateurs de la signalisation du tnf
TW201702247A (zh) 2015-04-17 2017-01-16 艾伯維有限公司 作為ｔｎｆ信號傳遞調節劑之吲唑酮
TW201710257A (zh) 2015-04-17 2017-03-16 艾伯維有限公司 Ｔｎｆ信號傳遞之三環調節劑
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
JP6968090B2 (ja) * 2016-04-01 2021-11-17 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
WO2017167996A1 (fr) 2016-04-01 2017-10-05 Ucb Biopharma Sprl Dérivés d'imidazole pentacycliques condensés utilisés en tant que modulateurs de l'activité du tnf
EA201892144A1 (ru) 2016-04-01 2019-04-30 Юсб Байофарма Спрл Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf
EP3436459B1 (fr) 2016-04-01 2021-08-25 UCB Biopharma SRL Dérivés d'imidazole pentacyclique fusionnés comme modulateurs de l'activité de la tnf
GB201620948D0 (en) 2016-12-09 2017-01-25 Ucb Biopharma Sprl Therapeutic agents
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
JP7121033B2 (ja) * 2017-03-15 2022-08-17 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
PT3615534T (pt) * 2017-04-25 2021-10-21 Sanofi Sa Derivados de imidazol pentacíclico fundido como moduladores da atividade do tnf
JP7429694B2 (ja) 2018-10-24 2024-02-08 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレータとしての縮合五環式イミダゾール誘導体
CN113683505A (zh) * 2021-09-29 2021-11-23 厦门大华本安化工安全研究院有限公司 一种含氧代环丁基的羧酸酯类化合物的制备方法
US20240247014A1 (en) * 2022-11-23 2024-07-25 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2024129763A1 (fr) * 2022-12-13 2024-06-20 Forward Therapeutics, Inc. MODULATEURS DE L'ACTIVITÉ DU TNF-α

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449649A3 (en) 1990-03-30 1992-09-02 Arizona Board Of Regents, Arizona State University Antineoplastic quinones and methods of using same
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
WO2004087720A1 (fr) 2003-03-10 2004-10-14 Pfizer Inc. Composes a base d'esters de sulfate/phosphate et compositions pharmaceutiques inhibant l'activite de nima interagissant avec des proteines (pin1)
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
ES2576298T3 (es) 2011-06-20 2016-07-06 Vertex Pharmaceuticals Incorporated Ésteres de fosfato de inhibidores de girasa y topoisomerasa
EP2858983B1 (fr) 2012-06-11 2018-04-18 UCB Biopharma SPRL Benzimidazoles modulant le tnf-alpha
US9309243B2 (en) * 2012-07-13 2016-04-12 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
JP6203954B2 (ja) 2013-10-25 2017-09-27 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN110840847B (zh) 2014-04-15 2022-07-29 沃泰克斯药物股份有限公司 用于治疗囊性纤维化跨膜传导调节因子介导的疾病的药物组合物
CN107108672B (zh) * 2014-10-03 2019-11-08 Ucb生物制药私人有限公司 稠合的五环咪唑衍生物

Also Published As

Publication number Publication date
US10202405B2 (en) 2019-02-12
CO2017003331A2 (es) 2017-09-29
EP3201196B1 (fr) 2021-07-28
CN107108672B (zh) 2019-11-08
ECSP17027306A (es) 2017-05-31
PL3201196T3 (pl) 2022-01-03
ES2885432T3 (es) 2021-12-13
IL251147B (en) 2020-05-31
CN107108672A (zh) 2017-08-29
US20170305932A1 (en) 2017-10-26
BR112017006669B1 (pt) 2023-04-18
KR102442235B1 (ko) 2022-09-08
US20210155637A1 (en) 2021-05-27
AU2015326798B2 (en) 2020-01-02
BR112017006669A2 (pt) 2017-12-26
US20190367535A1 (en) 2019-12-05
EA032839B1 (ru) 2019-07-31
AP2017009809A0 (en) 2017-03-31
LT3201196T (lt) 2021-09-27
NZ730256A (en) 2021-05-28
DK3201196T3 (da) 2021-09-06
TW201629067A (zh) 2016-08-16
RS62423B1 (sr) 2021-10-29
US10906919B2 (en) 2021-02-02
CA2962826A1 (fr) 2016-04-07
PE20170693A1 (es) 2017-06-13
JP2017531648A (ja) 2017-10-26
UY36341A (es) 2016-04-29
MX2017004201A (es) 2017-05-30
GT201700044A (es) 2019-09-09
CL2017000787A1 (es) 2017-11-24
MA40770A (fr) 2021-03-24
PH12017500414A1 (en) 2017-07-17
SI3201196T1 (sl) 2021-12-31
MY181019A (en) 2020-12-16
HRP20211605T1 (hr) 2022-01-21
CA2962826C (fr) 2023-08-08
HUE056133T2 (hu) 2022-01-28
EP3201196A1 (fr) 2017-08-09
WO2016050975A1 (fr) 2016-04-07
ZA201701946B (en) 2018-07-25
KR20170068503A (ko) 2017-06-19
TWI719949B (zh) 2021-03-01
JP6629847B2 (ja) 2020-01-15
CR20170167A (es) 2017-08-10
EA201790734A1 (ru) 2017-09-29
SG11201701796XA (en) 2017-04-27
UA120764C2 (uk) 2020-02-10
US11912721B2 (en) 2024-02-27
AU2015326798A1 (en) 2017-04-06
TN2017000083A1 (en) 2018-07-04
PH12017500414B1 (en) 2017-07-17
IL251147A0 (en) 2017-04-30

Similar Documents

Publication Publication Date Title
MA40770B1 (fr) Dérivés d'imidazoles pentacyclic fusionnés
BR112016012997A2 (pt) Derivados de benzimidazóis tricíclicos fundidos como moduladores de atividade de tnf
EA201500130A1 (ru) Производные имидазопиридина в качестве модуляторов активности tnf
BR112016012990A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
EA201500133A1 (ru) Производные имидазопиразина в качестве модуляторов активности tnf
CA2931589C (fr) Derives heteroaromatiques bicycliques condenses comme modulateurs de l'activite du tnf
BR112016013012A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
BR112016011483A2 (pt) Derivados de imidazotriazina como moduladores de atividade de tnf
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
BR112016011485A2 (pt) Derivados de imidazopiridazina como moduladores de atividade de tnf
TR201907702T4 (tr) Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri.
EA201892153A1 (ru) Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
BR112016012261A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
CU20160151A7 (es) 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
TR201910983T4 (tr) Tnf aktivitesinin modülatörleri olarak imidazotiazol türevleri.
BR112016012254A2 (pt) Derivados de triazolpiridazina como moduladores de atividade de tnf
EA201792686A1 (ru) Производные индазола в качестве модуляторов активности tnf
EA201792687A1 (ru) Конденсированные трициклические имидазопиразины в качестве модуляторов активности tnf
EA201892149A1 (ru) Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
EA201892142A1 (ru) Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
EA201892144A1 (ru) Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf
PH12019502182A1 (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
EA201991294A1 (ru) Замещенное производное бензимидазола в качестве модулятора активности tnf
MA45537B1 (fr) 1h-pyrazolo [4,3-b]pyridines en tant qu'inhibiteurs de pde1
MA41785A (fr) Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques